I would probably not sell today or tomorrow and might even consider buying depending on what happens here. This news is likely to cause many to sell or be forced to sell due to the other selling triggering stop limits and margin calls. But who knows what will end up happening.
CSTM has it beat, but I think if we look back 12 months from now, KERX will be in the pole position.
The answer would have to be a number, because you asked how many, not what are the names.
But I just wanted to bust yer balls a bit.
Davita and Fresnius will be the main drivers of US growth for KERX. They are more interested in pushing through the scrips than the average pharmacy, because they benefit from the scrip, to the extent that a patient on Auryxia requires less invasive dialysis (but still dialysis), with a reduction to IV iron and ESA therapy, with no corresponding reduction to the price they charge for the session. The losers will be competing phosphate binders, as well as iron and ESA med suppliers. And as the patient data reveals healthier and more stable patients with Auryxia, the greater system will follow suit.
Ferric Citrate will help lower the overall spend by taking out some of the IV iron and ESA expense. I believe Davita's study found it saved them like $9 bucks (maybe $7?) per dialysis session due to the average patient reduction in IV iron and ESA. And that does not even factor in the personal benefit to the patient of not having to experience IV iron, which is difficult, and which likely creates other medical expenses in its wake, as well as other economic costs to the individual in terms of reduced productivity and general well-being.
Good luck. I have allocated some to this fund this year as well, and am now wondering whether this or the passive vanguard international is the better way to go. I find it to be a tough call, but certainly agree that Europe is cheaper than the US.
If it doesn't go higher before your next few paychecks, put every extra penny into shares. This is a very cheap biotech, given the drug profile and probable use in the coming quarters.
Yes, a Yahoo and Fool article. How authorotative. I believe the writer is either biassed or does not use language well. I believe it is that he cannot write/speak well, because that is common and can frequently create vagueness, but it could be intentional. Here, rather than noting the actual profitability of the production that would be lost, if any, I believe the writer solely factors the expense of it being shuttered and/or the lost revenue, as though the business was running at a pure profit model and now has no inventory, though reality is opposite.
After the secondary offering, he implied that the investment banks were taking a bribe to not downgrade KERX. But the examples are numerous, and it is why he works for The Street, which is not a respected news source so much as a website that tries to get you to click through slideshows of #$%$ until you accidentally click on an ad.
No, it is not his fault it is down. And no, I do not own any shares. His fault is and ends with the fact that he knows many people follow his advice, despite all indications that it is more often than not bad advice, and that he told these followers, this week, that horizon was a buy. What is there to argue about that?
By the way, you are is contracted to you're.
I would probably sell my half of the moon for that, plus all the toenail fungus medication I can eat.